A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer

被引：0
|
作者：
Moore, M. J.
Tang, P.
Renouf, D.
Major, P.
Hedley, D.
Paterson, V.
Wang, L.
Dhesy-Thind, B.
Southwood, B.
Doyle, L.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Tom Baker Canc Clin, Calgary, AB, Canada
[3] Juravinski Canc Ctr, Hamilton, ON, Canada
[4] CTEP, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15634
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer
    Tsang, Erica S.
    Wong, Hui-li
    Wang, Ying
    Renouf, Daniel J.
    Cheung, Winson Y.
    Lim, Howard J.
    Gill, Sharlene
    Loree, Jonathan M.
    Kennecke, Hagen F.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (02): : 196 - 201
  • [42] Outcomes and characteristics of patients receiving second-line therapy for advanced pancreatic cancer
    Tsang, Erica S.
    Wong, Hui-Li
    Wang, Ying
    Renouf, Daniel John
    Cheung, Winson Y.
    Lim, Howard John
    Gill, Sharlene
    Loree, Jonathan M.
    Kennecke, Hagen F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [43] A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial
    Gitlitz, B. J.
    Davies, A. M.
    Belani, C. P.
    Argiris, A.
    Ramalingam, S. S.
    Hoffman, P. C.
    Koczwas, M.
    Groshen, S. G.
    Gandara, D. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Phase II Clinical Study on the GEMOX Regimen as Second-line Therapy for Advanced Ovarian Cancer
    Yuan, Shao-Fei
    Zhang, Lian-ping
    Zhu, Lin-Jia
    Chen, Wen-Jun
    Zheng, Wei-E
    Xiong, Jian-Ping
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (06) : 3949 - 3953
  • [45] Pharmacokinetics (PK) of E7389, a halichondrin B analog with novel antitubulin activity: Results of two phase I studies with different schedules of administration.
    Wong, N
    Desjardins, C
    Silberman, S
    Lewis, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 138S - 138S
  • [46] Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
    Eisen, Tim
    Thomas, Jose
    Miller, Wilson H., Jr.
    Gore, Martin
    Wolter, Pascal
    Kavan, Petr
    Lopez Martin, Jose A.
    Lardelli, Pilar
    [J]. MELANOMA RESEARCH, 2009, 19 (03) : 185 - 192
  • [47] A phase II study of a novel anti-tubulin, E7389, in patients with advanced non-small cell lung cancer (NSCLC).
    Das, A.
    Spira, A.
    Iannotti, N.
    Savin, M.
    Zang, E.
    Datta, K.
    Shapiro, G.
    Patturajan, M.
    Silberman, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 390S - 390S
  • [48] Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer
    Jivesh J. Sharma
    Betty Razvillas
    C.D. Stephens
    Susan G. Hilsenbeck
    Ashu Sharma
    Mace L. Rothenberg
    [J]. Investigational New Drugs, 1997, 15 : 361 - 364
  • [49] Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer
    Sharma, JJ
    Razvillas, B
    Stephens, CD
    Hilsenbeck, SG
    Sharma, A
    Rothenberg, ML
    [J]. INVESTIGATIONAL NEW DRUGS, 1997, 15 (04) : 361 - 364
  • [50] ERIBULIN MESYLATE (E7389) VS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC): SUBGROUP ANALYSES FROM THE EMBRACE STUDY
    Twelves, C.
    Akerele, C.
    Wanders, J.
    Cortes, J. A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 96 - 96
12345